Millenium's genetic maps of disease

Millenium Inc. plans to understand disease from the inside out by isolating disease-related genes. But unlike gene therapy companies, it will use the knowledge of those genes to develop a variety of therapeutics, ranging from protein replacement to small molecules.

"Over the past 15 years, companies have isolated interferons and growth factors and interleukins through molecular biology and protein chemistry, but they weren't necessarily related to a particular disease," said Mark Levin, acting CEO at Millenium. "Once a protein was found, then they would go into animal models and find out where they might be useful.